Logo

Regeneron Reports the US FDA Acceptance of sBLA for Priority Review of Dupixent (dupilumab) for the Treatment of Atopic Dermatitis

Share this

Regeneron Reports the US FDA Acceptance of sBLA for Priority Review of Dupixent (dupilumab) for the Treatment of Atopic Dermatitis

Shots:

  • The sBLA was based on the P-III trial evaluating the efficacy & safety of Dupixent added to TCS as an add-on maintenance treatment vs TCS alone in children aged 6mos. to 5yrs. with mod. to sev. AD whose disease is not adequately controlled with topical prescription therapies
  • The trial met all 1EPs & 2EPs i.e., the therapy showed an improvement in skin clearance and reduced overall disease severity and itch @16wks. The results were consistent with the safety profile of Dupixent for patients aged ≥6yrs.
  • The US FDA’s decision is expected on June 9, 2022. Dupixent is approved in the EU, Japan & other countries globally for use in specific patients with AD and asthma or CRSwNP

Ref: Regeneron | Image: The Print

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions